Navigation Links
ULURU Inc. Announces Closing Of $440,000 Private Placement
Date:3/15/2013

ADDISON, Texas, March 15, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR),a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced the completion of a definitive agreement to sell an aggregate of 1,100,000 shares of its common stock at a price per share of $0.40 pursuant to a previously announced private placement to management, resulting in gross proceeds of $440,000.  Participating in the private placement were Kerry P. Gray , the Company's Chairman, President and Chief Executive Officer and Terrance K. Wallberg , the Company's Vice President and Chief Financial Officer. 

The officers also received warrants to purchase up to an aggregate of 660,000 shares of ULURU Inc.'s common stock.  The warrants have a fixed exercise price of $0.60 per share and are exercisable at any time on or after 180 days from the closing date and for a period of five years from the date of closing.

Under the terms of the definitive agreement, the purchase and sale of the shares and warrants will take place at four closings over the next twelve months, with $88,000 being funded upon signing of the definitive agreement. 

The shares of common stock to be issued and any shares issued resulting from the exercise of warrants have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements.

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the anticipated closing of the transaction and the Company's products. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's lack of profitability, the need for additional capital to operate its business, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Third Quarter 2012 Financial Results
2. ULURU Inc. Announces The First Shipment Of Veterinary Product
3. ULURU Inc. Announces First Order Of Altrazeal For European Launch
4. ULURU Inc. Reports Second Quarter 2012 Financial Results
5. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
6. Cardica Announces Proposed Public Offering of Common Stock
7. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
8. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
9. Simbionix Announces License Agreement for Surgical Videos
10. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
11. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  As National Nutrition Month approaches, USA Medical ... is helping people live healthier lives by providing ... programs in all 50 states including:  Texas Prescription ... California Prescription Assistance Program . USA Medical ... for nutritious eating habits: ...
(Date:2/23/2017)... LG Innotek today announced that the company has developed the world,s ... is 1.5 times higher than the competitor,s 45mW module. ... of 200 -- 280nm, allowing it to be used for sterilization purpose. ... Innotek,s product emits UV in the range of 280nm. ... Until now, UV-C LED has ...
(Date:2/23/2017)... February 23, 2017 Tillotts Pharma ... Berlin office was opened in ... . The portfolio includes Entocort ® for the ... treatment of ulcerative colitis, and VistaPrep ® for ... Swiss specialty pharmaceutical company focused on the treatment of ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Thomas Vas-Don ... and disciplined exercise regime, the author was able to successfully recover. In “ Origin ... relevant information for various sources on the principals of massage, anatomy , ...
(Date:2/22/2017)... Raton, FL (PRWEB) , ... February 22, 2017 , ... ... primarily from deer antler velvet, announced its products are coming soon to Amazon.com, the ... Clint and Shelley Thomson as a means to develop an effective natural treatment for ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... Burlingame, CA (PRWEB) , ... February 22, 2017 ... ... of American adults with chronic conditions reported skipping doses or not filling a ... were uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
Breaking Medicine News(10 mins):